SUN-LB064 A Phase 2, Dose-Escalation, Safety and Efficacy Study of Tildacerfont (SPR001) for the Treatment of Patients with Classic Congenital Adrenal Hyperplasia

Kyriakie Sarafoglou; Ron Newfield; Maria Vogiatzi; Erik Imel; A. Odugbesan; Ivy-Joan Madu; Samer Nakhle; Alexis Howerton; Michael Huang; Kelly Vandever; Rong Lin; Alyssa Wu-Zhang; Richard Auchus

doi:10.1210/JS.2019-SUN-LB064

SUN-LB064 A Phase 2, Dose-Escalation, Safety and Efficacy Study of Tildacerfont (SPR001) for the Treatment of Patients with Classic Congenital Adrenal Hyperplasia

Kyriakie Sarafoglou
, Ron Newfield
, Maria Vogiatzi
, Erik Imel
, A. Odugbesan
, Ivy-Joan Madu
, Samer Nakhle
, Alexis Howerton
, Michael Huang
, Kelly Vandever
, Rong Lin
, Alyssa Wu-Zhang
, Richard Auchus

University of Minnesota
University of California, San Diego
Children's Hospital of Philadelphia
Indiana University – Purdue University Indianapolis
North Atlanta Endocrinology & Diabetes PC, Lawrenceville, GA, United States
DIABETES ASSOCIATES MEDICAL GROUP, Diabetes Associates Medical Group, Orange, CA, United States
Palm Medical Group, Las Vegas, NV, United States
Spruce Biosciences, San Francisco, CA, United States
Biostatistical Consulting, Inc, Lexington, MA, United States
Biomedical writing consultant, San Jose, CA, United States
University of Michigan

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Journal of the Endocrine Society
Volume	3
DOIs	https://doi.org/10.1210/JS.2019-SUN-LB064
State	Published - Apr 15 2019
Externally published	Yes

Disciplines

Medicine and Health Sciences
Urology

Access to Document

10.1210/JS.2019-SUN-LB064License: Unspecified

Cite this

Sarafoglou, K., Newfield, R., Vogiatzi, M., Imel, E., Odugbesan, A., Madu, I.-J., Nakhle, S., Howerton, A., Huang, M., Vandever, K., Lin, R., Wu-Zhang, A., & Auchus, R. (2019). SUN-LB064 A Phase 2, Dose-Escalation, Safety and Efficacy Study of Tildacerfont (SPR001) for the Treatment of Patients with Classic Congenital Adrenal Hyperplasia. Journal of the Endocrine Society, 3. https://doi.org/10.1210/JS.2019-SUN-LB064

Sarafoglou, K, Newfield, R, Vogiatzi, M, Imel, E, Odugbesan, A, Madu, I-J, Nakhle, S, Howerton, A, Huang, M, Vandever, K, Lin, R, Wu-Zhang, A & Auchus, R 2019, 'SUN-LB064 A Phase 2, Dose-Escalation, Safety and Efficacy Study of Tildacerfont (SPR001) for the Treatment of Patients with Classic Congenital Adrenal Hyperplasia', Journal of the Endocrine Society, vol. 3. https://doi.org/10.1210/JS.2019-SUN-LB064

@article{fe0d2ff3c0c8401ca8a6f20fbbb5283f,

title = "SUN-LB064 A Phase 2, Dose-Escalation, Safety and Efficacy Study of Tildacerfont (SPR001) for the Treatment of Patients with Classic Congenital Adrenal Hyperplasia",

author = "Kyriakie Sarafoglou and Ron Newfield and Maria Vogiatzi and Erik Imel and A. Odugbesan and Ivy-Joan Madu and Samer Nakhle and Alexis Howerton and Michael Huang and Kelly Vandever and Rong Lin and Alyssa Wu-Zhang and Richard Auchus",

note = "Abstract. Background: Congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency is characterized by impaired cortisol synthesis leading to excess ad",

year = "2019",

month = apr,

day = "15",

doi = "10.1210/JS.2019-SUN-LB064",

language = "American English",

volume = "3",

journal = "Journal of the Endocrine Society",

}

TY - JOUR

T1 - SUN-LB064 A Phase 2, Dose-Escalation, Safety and Efficacy Study of Tildacerfont (SPR001) for the Treatment of Patients with Classic Congenital Adrenal Hyperplasia

AU - Sarafoglou, Kyriakie

AU - Newfield, Ron

AU - Vogiatzi, Maria

AU - Imel, Erik

AU - Odugbesan, A.

AU - Madu, Ivy-Joan

AU - Nakhle, Samer

AU - Howerton, Alexis

AU - Huang, Michael

AU - Vandever, Kelly

AU - Lin, Rong

AU - Wu-Zhang, Alyssa

AU - Auchus, Richard

N1 - Abstract. Background: Congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency is characterized by impaired cortisol synthesis leading to excess ad

PY - 2019/4/15

Y1 - 2019/4/15

UR - https://academic.oup.com/jes/article/3/Supplement_1/SUN-LB064/5484473

U2 - 10.1210/JS.2019-SUN-LB064

DO - 10.1210/JS.2019-SUN-LB064

M3 - Article

VL - 3

JO - Journal of the Endocrine Society

JF - Journal of the Endocrine Society

ER -

SUN-LB064 A Phase 2, Dose-Escalation, Safety and Efficacy Study of Tildacerfont (SPR001) for the Treatment of Patients with Classic Congenital Adrenal Hyperplasia

Disciplines

Access to Document

Other files and links

Cite this